Titan Pharmaceuticals, Inc. (TTNP)
| Market Cap | 22.24M |
| Revenue (ttm) | 741,000 |
| Net Income (ttm) | -9.46M |
| Shares Out | 14.63M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,920 |
| Open | 1.53 |
| Previous Close | 1.58 |
| Day's Range | 1.51 - 1.59 |
| 52-Week Range | 0.35 - 2.38 |
| Beta | 1.20 |
| Analysts | Sell |
| Price Target | 7.14 (+369.7%) |
| Earnings Date | Aug 15, 2022 |
About TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the p... [Read more...]
Financial Performance
In 2021, TTNP's revenue was $1.53 million, a decrease of -68.46% compared to the previous year's $4.84 million. Losses were -$8.78 million, -51.89% less than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for TTNP stock is "Sell." The 12-month stock price forecast is 7.14, which is an increase of 369.74% from the latest price.
News
Titan Pharmaceuticals Announces Board Expansion and Management Changes
SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Board"...
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
SOUTH SAN FRANCISCO, Calif. , July 5, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cl...
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholder...
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), today filed a Schedule 13D announcing its acquisition of approximately 5...
Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find profit...
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market
SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement w...
Titan Pharmaceuticals to Explore Strategic Alternatives
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate s...
Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021
SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscie...
Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model of...
Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in ...
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gate...
Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license ag...
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic ...
SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," former...
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decembe...
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Develo...
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potenc...
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institut...
Titan Pharmaceuticals Announces Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 rever...
Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30...
7 Penny Stocks to Watch in November
Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0....
Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Know about the JT Pharma Deal
Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Kn...
Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing...
Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved th...
Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.